Search
Netupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy … The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
CX-052075
go.drugbank.com/drugs/DB31655Approved[L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586] … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Human papillomavirus type 33 L1 capsid protein antigen
go.drugbank.com/drugs/DB10311ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33. … Human papillomavirus type 33 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTIONHuman papillomavirus type 45 L1 capsid protein antigen
go.drugbank.com/drugs/DB10312ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 45. … Human papillomavirus type 45 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTIONHuman papillomavirus type 58 L1 capsid protein antigen
go.drugbank.com/drugs/DB10314ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58. … Human papillomavirus type 58 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection.
Mixtures: GARDASIL 9 SUSPENSION FOR INJECTIONMeningococcal polysaccharide vaccine group W-135
go.drugbank.com/drugs/DB13887ApprovedInvestigationalIt is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.
Mixtures: MENVEO POWDER & SOLUTION FOR SOLUTION FOR INJECTION, Menveo Powder and Solution for Solution for InjectionMephenytoin
go.drugbank.com/drugs/DB00532ApprovedWithdrawnMephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. … These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha.
Remimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigational[A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722] … susceptible to rapid biotransformation and elimination as inactive metabolites.
Moxetumomab pasudotox
go.drugbank.com/drugs/DB12688ApprovedInvestigational[A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW. … This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the _Pseudomonas_ exotoxin A (PE38) which does not have the cell-binding portion
Doxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigationalDoxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. … [A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Categories: Antihypertensive Agents Indicated for HypertensionProducts: DOXAZOSIN 1 COR 1A PHARMA, DOXAZOSIN 2 COR 1A PHARMA